estimates, target were boosted at Morgan Stanley. Shares are now seen reaching $210, according to Morgan Stanley. Estimates also upped, given higher marketing solutions growth. Overweight rating.
estimates, target were cut at Canaccord. Shares are now seen reaching $3.50, according to Canaccord Genuity. Estimates also reduced, as the company is likely losing market share to Samsung. Hold rating.
price target and earnings estimates through 2014 were increased at Citi. Soybeans should drive growth starting in 2014 and the accelerated buyback is also a catalyst, said Citigroup. Price target goes to $122.
Monsanto estimates, target raised at Piper as the company is carrying a lot of momentum into the planting season. Overweight rating.
New York Community Bancorp
estimates were reduced at Citi through 2014 to reflect a soft quarter. Lower pre-payments and margins are expected and the anticipated accretive merger is unlikely to happen, said Citigroup.
price target increased to $87 at UBS. Industry commentary has been positive, top line momentum remains intact and productivity and capital deployment will benefit the company, said UBS.
price target and estimates were reduced given the introduction of a generic version of Zovirax Ointment, said UBS. Price target goes to $81.
>To submit a news tip, email:
and become a fan on